Superluminal Medicines Valuation Estimate
Superluminal Medicines Valuation as of Last Funding Round
Superluminal Medicines Company Overview
Superluminal Medicines specializes in generative biology medicine technology aimed at enhancing drug discovery processes. The company focuses on creating candidate-ready compounds through a blend of deep biology and chemistry expertise, machine learning, and a robust big data infrastructure. This approach supports the pharmaceutical industry by streamlining drug discovery and improving the likelihood of success in small molecule drug development.
Superluminal Medicines Valuation History
FAQ
Does Superluminal Medicines have stock?
Yes, Superluminal Medicines and almost all privately held companies issue stock so founders, employees, and investors can participate in equity ownership. However, because Superluminal Medicines is privately held, it is more challenging to acquire shares than if the company was publicly traded.
Is Superluminal Medicines publicly traded?
No, Superluminal Medicines is a privately held company. It is not publicly traded or offered directly on any stock exchange like the NYSE, Nasdaq, etc.
Who owns Superluminal Medicines stock?
As a privately held company, Superluminal Medicines shares are held by its founders, management, employees, venture capital funds, or other private individuals and institutional investors.
Disclosure rules differ for private and public companies, so it may not always be possible to know the complete ownership (cap table) of a private company like Superluminal Medicines.
What is the stock symbol for Superluminal Medicines?
Superluminal Medicines is a privately held company. Therefore, it does not have a stock symbol or “ticker” that trades on public exchanges like the NYSE, Nasdaq, etc.
Can I buy Superluminal Medicines stock on UpMarket?
If you would like to buy shares in Superluminal Medicines, please provide your information in the form at the top of this page and click the button titled “I want to buy this stock.”
One of our investor relations team members will contact you to discuss Superluminal Medicines stock availability. Note: inquiries are non-binding, subject to market availability, and shares may only be purchased by accredited investors that meet all eligibility criteria.
UpMarket has offered many similar companies as Pre-IPO investments, including Airbnb, SpaceX, ByteDance, Plaid, Kraken, Databricks, and others. UpMarket also often has funds available that invest in a portfolio of companies potentially including, Superluminal Medicines as well.
What is Superluminal Medicines stock price?
The stock price of Superluminal Medicines can be calculated by taking the valuation of the company divided by the number of shares outstanding. Because a private company can issue new shares at any time, we do not know the current number of shares outstanding.
For illustrative purposes, however, assuming Superluminal Medicines has issued 250 million shares, at the estimated UpMarket valuation of $158.40 million, each share of Superluminal Medicines stock would be worth $0.63.
How do Superluminal Medicines pre-IPO trades work?
Pre-IPO trades for Superluminal Medicines will typically involve accredited investors purchasing shares from current shareholders through specialized investment platforms like UpMarket. Trades generally occur on the secondary market, meaning Superluminal Medicines doesn't issue new shares or receive capital–shares are privately exchanged between two parties.
While investors aim to profit from a potential IPO or acquisition, these investments carry high risks due to limited liquidity and information. Understanding all terms and conditions is crucial, as each transaction can have unique characteristics. Investing in private companies can be extremely risky and may result in significant capital loss.
When is Superluminal Medicines going to go public?
The decision to go public through an Initial Public Offering (IPO) is complex and depends on various factors, including the company's financial performance, market conditions, and strategic goals.
Unless Superluminal Medicines officially announces its intention to go public, any predictions about when or if it will do so would be speculative.
Investors interested in Superluminal Medicines should monitor official company communications and reliable financial news sources for any updates regarding potential IPO plans.
How do I exit my investment if I invest in Superluminal Medicines with UpMarket?
Exiting your investment in Superluminal Medicines typically involves one of these scenarios: 1) selling your shares on a secondary market to other interested investors; 2) holding shares until a liquidity event occurs, such as the company going public (IPO) or being acquired.
Investors must know that the timing and availability of these exit options are inherently unpredictable, and there is no guarantee of when or if they will occur.
How can I sell Superluminal Medicines shares?
If you own Superluminal Medicines shares, you may be able to find a buyer on a pre-IPO marketplace or via an introduction by a registered broker-dealer like UpMarket. It is important to note that the class of shares you own may impact your ability to sell. For example, shares issued to startup employees often have transaction limitations, including lock-up periods and a right of first refusal by the company, which may prevent you from selling your shares freely.
How does UpMarket estimate the valuation of Superluminal Medicines?
UpMarket’s valuation estimate for Superluminal Medicines is algorithmically generated based on recent primary round financings by Superluminal Medicines, market conditions, company popularity, sector performance, and public market comps.
It is important to note that UpMarket’s valuation estimate for Superluminal Medicines could be outdated, may not reflect all recent news or market events, and is not intended to inform any investment decision-making. UpMarket’s valuation estimate is not meant to be a warranty or projection of potential financial returns or company performance. Valuations can change rapidly and unexpectedly.
Why choose UpMarket?
UpMarket was founded in 2019 and has helped hundreds of investors access alternative investments. UpMarket is a licensed broker-dealer based in the United States. UpMarket customers have invested over $150 million in pre-IPO companies, hedge funds, private equity, real estate, and other alternatives.
If you are an accredited investor, you can create a free account to access our deal flow and opportunities. There is never any pressure to invest.
UpMarket clients have invested in companies like
Superluminal Medicines,
SpaceX, Neuralink, Anthropic, and many others. UpMarket and its leadership have been mentioned in media outlets like Forbes, WealthManagement, Wealth and Finance News, and TechBullion.
Superluminal Medicines Management
| Name | Position |
|---|---|
| Cony D'Cruz | CEO |
